Debbie Bensen‐Kennedy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Debbie Bensen‐Kennedy has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Annette von Drygalski
Division of Hematology/Oncology, Department of Medicine, University of California San Diego, San Diego, CA
2 shared publications - Clive A. Smith
GlaxoSmithKline Pharmaceuticals, New Frontiers Science Park, Third Avenue, Harlow, UK
2 shared publications - Douglass Drelich
CSL Behring, King of Prussia, USA
2 shared publications - Karen Pinachyan
CSL Behring , Hattersheim am Main , Germany
2 shared publications - Krupa Sivamurthy
CSL Behring King of Prussia Pennsylvania USA
2 shared publications - Roshni Kulkarni
Michigan State University
2 shared publications
Latest Publications
- 15 February 2024
- Published by Wiley in European Journal of Haematology
- Vol. 112 (3)
Featured Cover
- Open Access
- 11 December 2023
- Published by Wiley in European Journal of Haematology
- Vol. 112 (3) , 339-349
The current challenges faced by people with hemophilia B
Hemophilia B (HB) is a rare, hereditary disease caused by a defect in the gene encoding factor IX (FIX) and leads to varying degrees of coagulation deficiency. The prevailing treatment for people with HB (PWHB) is FIX replacement product. The advent of recombinant coagulation products ushered in a new era of safety, efficacy, and improved availability compared with plasma‐derived products. For people with severe HB, lifelong prophylaxis with a FIX replacement product is standard of care. Development of extended half‐life FIX replacement products has allowed for advancements in the care of these PWHB. Nonetheless, lifelong need for periodic dosing and complex surveillance protocols pose substantive challenges in terms of access, adherence, and healthcare resource utilization. Further, some PWHB on prophylactic regimens continue to experience breakthrough bleeds and joint damage, and subpopulations of PWHB, including women, those with mild‐to‐moderate HB, and those with inhibitors to FIX, experience additional unique difficulties. This review summarizes the current challenges faced by PWHB, including the unique subpopulations; identifying the need for improved awareness, personalized care strategies, and new therapeutic options for severe HB, which may provide future solutions for some of the remaining unmet needs of PWHB.
- 11 December 2023
- Published by Wiley in European Journal of Haematology
- Vol. 112 (3) , 339-349
Open AccessThe current challenges faced by people with hemophilia B
Hemophilia B (HB) is a rare, hereditary disease caused by a defect in the gene encoding factor IX (FIX) and leads to varying degrees of coagulation deficiency. The prevailing treatment for people with HB (PWHB) is FIX replacement product. The advent of recombinant coagulation products ushered in a new era of safety, efficacy, and improved availability compared with plasma‐derived products. For people with severe HB, lifelong prophylaxis with a FIX replacement product is standard of care. Development of extended half‐life FIX replacement products has allowed for advancements in the care of these PWHB. Nonetheless, lifelong need for periodic dosing and complex surveillance protocols pose substantive challenges in terms of access, adherence, and healthcare resource utilization. Further, some PWHB on prophylactic regimens continue to experience breakthrough bleeds and joint damage, and subpopulations of PWHB, including women, those with mild‐to‐moderate HB, and those with inhibitors to FIX, experience additional unique difficulties. This review summarizes the current challenges faced by PWHB, including the unique subpopulations; identifying the need for improved awareness, personalized care strategies, and new therapeutic options for severe HB, which may provide future solutions for some of the remaining unmet needs of PWHB.